黑色素瘤手术切除后辅助使用伊匹单抗的罕见副作用：吉兰-巴雷综合征。
Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome.
作者信息
Patel Rohini J, Liu Michael A, Amaraneni Akshay, Sindhu Simran K
机构信息
Division of Hematology-Oncology, The University of Arizona Cancer Center, Tucson, Arizona, USA.
出版信息
BMJ Case Rep. 2017 Dec 13;2017:bcr-2017-221318. doi: 10.1136/bcr-2017-221318.
Abstract
Guillain-Barré syndrome is a life-threatening neurological disorder that presents with rapid ascending paralysis and areflexia. Guillain-Barré syndrome is traditionally associated with infections from a gastrointestinal or respiratory tract source. We report the case of a 71-year-old man with melanoma who was treated with ipilimumab as adjuvant immunotherapy and subsequently developed Guillain-Barré syndrome. The diagnosis was made clinically through physical exam findings. He was successfully treated with a combination of intravenous immunoglobulin therapy and corticosteroids.
摘要
吉兰-巴雷综合征是一种危及生命的神经系统疾病，表现为快速进展的瘫痪和腱反射消失。传统上，吉兰-巴雷综合征与胃肠道或呼吸道来源的感染有关。我们报告了一例71岁的黑色素瘤男性患者，该患者接受了伊匹木单抗辅助免疫治疗，随后发生了吉兰-巴雷综合征。通过体格检查结果进行临床诊断。他通过静脉注射免疫球蛋白治疗和皮质类固醇联合治疗获得成功治愈。
相似文献
1
Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome.黑色素瘤手术切除后辅助使用伊匹单抗的罕见副作用：吉兰-巴雷综合征。
BMJ Case Rep. 2017 Dec 13;2017:bcr-2017-221318. doi: 10.1136/bcr-2017-221318.
2
Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.易普利姆玛诱导的吉兰-巴雷综合征表现为自主神经功能障碍：免疫治疗罕见并发症的一种不寻常表现。
J Immunother. 2017 Jun;40(5):196-199. doi: 10.1097/CJI.0000000000000167.
3
A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.1 例严重的依匹单抗诱导的吉兰-巴雷综合征：一种不同于依匹单抗诱导结肠炎的鉴别诊断。
J Immunother. 2013 Jan;36(1):77-8. doi: 10.1097/CJI.0b013e31827807dd.
4
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.纳武利尤单抗辅助治疗与伊匹单抗用于切除的 III 期或 IV 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
5
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.伊匹木单抗诱导的吉兰-巴雷综合征后安全过渡至帕博利珠单抗：一例病例报告及文献复习
Case Rep Oncol Med. 2019 Nov 22;2019:5490707. doi: 10.1155/2019/5490707. eCollection 2019.
6
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.与辅助用伊匹单抗相关的神经免疫相关不良反应：两例报告。
J Immunother Cancer. 2018 Aug 31;6(1):83. doi: 10.1186/s40425-018-0393-z.
7
Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.免疫检查点抑制剂引发的吉兰-巴雷综合征：一例报告及文献综述
J Clin Neuromuscul Dis. 2017 Dec;19(2):80-83. doi: 10.1097/CND.0000000000000193.
8
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.纳武单抗诱导的慢性炎性脱髓鞘性多发性神经根神经病酷似快速进展型吉兰-巴雷综合征：一例报告
Jpn J Clin Oncol. 2016 Sep;46(9):875-8. doi: 10.1093/jjco/hyw090. Epub 2016 Jul 5.
9
Guillain-Barré syndrome with associated unilateral ptosis without ophthalmoplegia - a rare presentation: a case report and review of the literature.伴有单侧上睑下垂但无眼肌麻痹的吉兰-巴雷综合征——一种罕见表现：病例报告及文献复习
J Med Case Rep. 2019 Jul 20;13(1):221. doi: 10.1186/s13256-019-2157-x.
10
[Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].[皮质类固醇和免疫球蛋白联合成功治疗派姆单抗引起的吉兰-巴雷综合征样急性炎症性脱髓鞘性多发性神经病：病例报告]
Rinsho Shinkeigaku. 2020 Nov 27;60(11):773-777. doi: 10.5692/clinicalneurol.cn-001444. Epub 2020 Oct 27.
引用本文的文献
1
Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data.吉兰-巴雷综合征与检查点抑制剂疗法：来自药物警戒数据的见解
BMJ Neurol Open. 2024 Mar 13;6(1):e000544. doi: 10.1136/bmjno-2023-000544. eCollection 2024.
2
Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.免疫检查点抑制剂相关格林-巴利综合征样多发性神经病：33 例病例的系统评价
Biomed Res Int. 2021 Aug 19;2021:9800488. doi: 10.1155/2021/9800488. eCollection 2021.
3
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.伊匹木单抗诱导的吉兰-巴雷综合征后安全过渡至帕博利珠单抗：一例病例报告及文献复习
Case Rep Oncol Med. 2019 Nov 22;2019:5490707. doi: 10.1155/2019/5490707. eCollection 2019.
4
Neurological syndromes driven by postinfectious processes or unrecognized persistent infections.由感染后过程或未被识别的持续性感染驱动的神经综合征。
Curr Opin Neurol. 2018 Jun;31(3):318-324. doi: 10.1097/WCO.0000000000000553.
本文引用的文献
1
Neurological toxicities associated with immune-checkpoint inhibitors.与免疫检查点抑制剂相关的神经毒性。
Curr Opin Neurol. 2017 Dec;30(6):659-668. doi: 10.1097/WCO.0000000000000503.
2
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
3
Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.易普利姆玛诱导的吉兰-巴雷综合征表现为自主神经功能障碍：免疫治疗罕见并发症的一种不寻常表现。
J Immunother. 2017 Jun;40(5):196-199. doi: 10.1097/CJI.0000000000000167.
4
Guillain-Barré Syndrome.吉兰-巴雷综合征
Mayo Clin Proc. 2017 Mar;92(3):467-479. doi: 10.1016/j.mayocp.2016.12.002.
5
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.高危III期黑色素瘤完全切除术后辅助使用伊匹单抗与安慰剂相比的健康相关生活质量（EORTC 18071）：一项多国、随机、双盲、3期试验的次要结果
Lancet Oncol. 2017 Mar;18(3):393-403. doi: 10.1016/S1470-2045(17)30015-3. Epub 2017 Feb 3.
6
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.伊匹单抗辅助治疗Ⅲ期黑色素瘤的长期生存
N Engl J Med. 2016 Nov 10;375(19):1845-1855. doi: 10.1056/NEJMoa1611299. Epub 2016 Oct 7.
7
Neurologic complications of immune checkpoint inhibitors.免疫检查点抑制剂的神经系统并发症
Curr Opin Neurol. 2016 Dec;29(6):806-812. doi: 10.1097/WCO.0000000000000391.
8
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.抗程序性死亡蛋白1（PD-1）疗法的神经、呼吸、肌肉骨骼、心脏及眼部副作用。
Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13.
9
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.与抗CTLA-4抗体相关的免疫相关不良事件：系统评价与荟萃分析。
BMC Med. 2015 Sep 4;13:211. doi: 10.1186/s12916-015-0455-8.
10
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.辅助伊匹单抗对比安慰剂用于完全切除的高风险 III 期黑色素瘤（EORTC 18071）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31.
Zotero 插件